Niklas Mattsson-Carlgren on the use of biomarkers in the diagnosis and stratification of Alzheimer’s disease
About this episode
This episode features a discussion on the use of blood biomarkers in diagnosing and stratifying Alzheimer's disease.
In this episode, Laura Hart and Elena Becker-Barroso speak with Niklas Mattsson-Carlgren (Lund University) about the use of blood biomarkers in the diagnosis and stratification of Alzheimer's disease. They discuss two particular plasma biomarkers—p-tau217 and eMTBR-tau243—including what they measure and how a proposed practical two-step approach that uses p-tau217 as an initial screen in a neurology clinic, and then eMTBR-tau243 for those who test positive, could support diagnostic decisions....
More episodes of The Lancet Neurology in conversation with
- Jan D Lünemann and Christian Münz on Epstein–Barr virus and multiple sclerosis
- Hal Dietz discusses the role of genetics in spinal CSF leaks
- Tony Schapira on GBA1 Parkinson's disease
- Cristina Tassorelli on migraine prevention
- Inga Zerr and Simon Mead on advances in prion diseases
- Julia Greenland on azathioprine for early Parkinson’s disease
Explore listener stats, chart rankings, contacts and more on the The Lancet Neurology in conversation with podcast page.